medigraphic.com
Asociación Mexicana de Gastroenterología

2005, Number 4

<< Back Next >>

Rev Gastroenterol Mex 2005; 70 (4)

First National Consensus on Chronic Hepatitis B

Marín LER

Language: Spanish
References: 41
Page: 490-503
PDF size: 66.78 Kb.


ABSTRACT

This is the first time in our country that a group of experts in the field of hepatology gather to review the current status of HBV infection establishing the First National Consensus on Chronic Hepatitis B. With the new sensitive diagnostic methods, new antivirals capable of inhibiting viral replication, the appropriate use of passive and active immunoprophilaxis, and the better understanding of the natural history of the disease, we are finding new corners in the approach of high risk groups and management of infected patients. The National Consensus on Chronic Hepatitis B reunited 34 Mexican leaders in Hepatology, Gastroenterology, Infectology, Pediatrics, Oncology, Pathology and Molecular Biology. During these rounds the need of incorporating new knowledge on Hepatitis B in our daily clinical practice was analyzed in a way to transform Hepatitis B to an understandable and easy subject. Also, the fears on the knowledge of basic molecular biology, practical analysis of serologic markers, and diagnostic methodology as well as use and indications for new therapeutic agents was also discussed. This is a first consensus.


REFERENCES

  1. Epidemiología y prevención


  3. Alter M. Epidemiology and prevention of hepatitis B. Sem Liv Dis 2003; 23: 39-46.

  4. McQuillan GM, Coleman PJ, Kruszon-Moran D, et al. Prevalence of hepatitis B virus infection in the United States. The National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999; 89: 14-18.

  5. Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and common mutants. Sem Liv Dis 2003; 23: 20.

  6. Kershenobich D, Hurtado R, Collawn, C, et al. Rev Invest Clin 1990; 4: 251-6.

  7. Alberu, J, Lisker-Melman M., Gonzalez M, et al. Transplant Proc 1996; 28(6): 3298.

  8. 6. Tanaka J. Hepatitis B epidemiology in Latin America. Vaccine 2000; 18(Suppl. 1): S17-9.


  10. Diagnóstico


  12. Lok A, McMahon B. Chronic hepatitis B. Hepatology 2001; 34: 1225-41.

  13. Lung C, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-94.

  14. Lee W. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.

  15. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-24.

  16. Mendez-Sanchez N, Aguilar-Ramirez JR, Reyes A, et al. Etiology of liver cirrhosis in Mexico. Ann Hepatol 2004; 3(1): 30-3.


  18. Progresión


  20. McMahon BJ, Alward WLM, Hall DB, et al. Acute hepatitis B infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151: 599-603.

  21. De Jongh FE, Janssen HL, de Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-5.

  22. Fattovich G. Natural history and prognosis of hepatitis B. Sem Liv Dis 2003; 23: 47-58.


  24. Tratamiento y recomendaciones de manejo


  26. Keeffe E, Dieterich D, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatology 2004; 2: 87-106.

  27. Lok A, Heathcote J, Hoofnagle J. Management of hepatitis B: 2000-Summary of a workshop. Gastroenterology 2001; 120: 1828-53.

  28. Esteban R. Management of chronic hepatitis B. Sem Liv Dis 2002; 22(S1): S1-S6.

  29. Hadziyannis S, Papatheodoridis G, Vassilopoulos D. Treatment of HbeAg-Negative Chronic Hepatitis B. Sem Liv Dis 2003; 23: 81-8.

  30. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.

  31. Hadziyannis SJ, Tassopoulos N, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.

  32. Heathcote J. Treatment of HBe antigen-positive chronic hepatitis B. Sem Liv Dis 2003; 23: 69-80.

  33. Marcellin P. Advances in therapy for chronic hepatitis B. Sem Liv Dis 2003; 23: 33-6.


  35. Grupos especiales


  37. Fontana R. Management of patients with decompensated HBV cirrhosis. Sem Liv Dis 2003; 23: 89-100.

  38. Broderick A, Jonas M. Hepatitis B in Children. Sem Liv Dis 2003; 23: 59-68.

  39. Benhamou Y. Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358: 718-23.

  40. Puoti M, et al. AIDS Rev 2002; 4: 27-35.

  41. Thomas C, et al. AIDS Patient Care 2003; 17: 623-33.




2020     |     www.medigraphic.com